Nykode Therapeutics AS Cash Flow
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
2022
2021
2020
2019
-21M
-43M
2M
4M
-1M
26M
10M
3M
0M
0M
-0 %
0M
-1M
0M
206M
-10M
216M
-23M
1M
-9M
1M
3M
0M
8M
11M
1M
20M
0M
-0 %
0M
-1M
0M
216M
32M
184M
0M
180M
150M
0M
3M
0M
-5M
-6M
0M
0M
0M
0 %
0M
0M
0M
184M
174M
10M
180M
-10M
-96M
0M
0M
0M
1M
-9M
0M
26M
0M
-0 %
0M
0M
0M
32M
6M
16M
-10M
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
4Q2021
-13M
-10M
1M
1M
0M
-2M
-1M
1M
0M
0M
-0 %
0M
0M
0M
159M
-15M
174M
-14M
-16M
-9M
1M
1M
-2M
-5M
4M
0M
0M
0M
-0 %
0M
0M
0M
174M
-13M
186M
-16M
-16M
-10M
1M
1M
-2M
-7M
-1M
0M
0M
0M
-0 %
0M
0M
0M
186M
-13M
206M
-21M
-11M
-12M
0M
1M
-4M
4M
0M
0M
2M
0M
-0 %
0M
1M
0M
206M
-6M
212M
-11M
-8M
-15M
0M
1M
4M
6M
9M
0M
-2M
0M
-0 %
0M
-2M
0M
212M
-1M
213M
-8M
-13M
-9M
0M
1M
0M
-3M
1M
0M
0M
0M
-0 %
0M
0M
0M
213M
-12M
226M
-13M
11M
-7M
0M
1M
0M
18M
-2M
2M
0M
0M
-0 %
0M
0M
0M
226M
9M
216M
9M
21M
11M
0M
1M
0M
5M
3M
1M
0M
0M
0 %
0M
0M
0M
216M
43M
173M
20M